journal article·2016-11

Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth

Sung Eun Kim, Li Zhang, Kai Ma, Michelle Riegman, Feng Chen, Irina Ingold, Marcus Conrad, Melik Ziya Turker, Minghui Gao, Xuejun Jiang, Sebastien Monette, Mohan Pauliah, Mithat Gonen, Pat Zanzonico, Thomas Quinn, Ulrich Wiesner, Michelle S. Bradbury, Michael Overholtzer

Nature Nanotechnology· Volume 11· Issue 11
Publisher page

Abstract

The design of cancer-targeting particles with precisely tuned physicochemical properties may enhance the delivery of therapeutics and access to pharmacological targets. However, a molecular-level understanding of the interactions driving the fate of nanomedicine in biological systems remains elusive. Here, we show that ultrasmall (<10 nm in diameter) poly(ethylene glycol)-coated silica nanoparticles, functionalized with melanoma-targeting peptides, can induce a form of programmed cell death known as ferroptosis in starved cancer cells and cancer-bearing mice. Tumour xenografts in mice intravenously injected with nanoparticles using a high-dose multiple injection scheme exhibit reduced growth or regression, in a manner that is reversed by the pharmacological inhibitor of ferroptosis, liproxstatin-1. These data demonstrate that ferroptosis can be targeted by ultrasmall silica nanoparticles and may have therapeutic potential.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · RNA modifications and cancer · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (32)

Show source-provided references
1. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008).10.1038/nrd2614 ↗
2. Phillips, E. et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6, 260ra149 (2014).10.1126/scitranslmed.3009524 ↗
3. Duncan, R. & Richardson, S. C. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol. Pharmacol. 9, 2380–2402 (2012).10.1021/mp300293n ↗
4. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharmacol. 8, 2101–2141 (2011).10.1021/mp200394t ↗
5. Ma, X. et al. Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano 5, 8629–8639 (2011).10.1021/nn202155y ↗
6. Li, J. J., Hartono, D., Ong, C. N., Bay, B. H. & Yung, L. Y. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials 31, 5996–6003 (2010).10.1016/j.biomaterials.2010.04.014 ↗
7. Chen, N. et al. Long-term effects of nanoparticles on nutrition and metabolism. Small 10, 3603–3611 (2014).10.1002/smll.201303635 ↗
8. Li, C. et al. PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J. Mol. Cell Biol. 1, 37–45 (2009).10.1093/jmcb/mjp002 ↗
9. Stern, S. T., Adiseshaiah, P. P. & Crist, R. M. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part. Fibre Toxicol. 9, 20 (2012).10.1186/1743-8977-9-20 ↗
10. Ma, K. et al. Control of ultrasmall sub-10 nm ligand-functionalized fluorescent core–shell silica nanoparticle growth in water. Chem. Mater. 27, 4119–4133 (2015).10.1021/acs.chemmater.5b01222 ↗
11. Bradbury, M. S. et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr. Biol. (Camb.) 5, 74–86 (2013).10.1039/c2ib20174g ↗
12. Benezra, M. et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768–2780 (2011).10.1172/JCI45600 ↗
13. Yoo, B. et al. Ultrasmall dual-modality silica nanoparticle drug conjugates: design, synthesis, and characterization. Bioorg. Med. Chem. 23, 7119–7130 (2015).10.1016/j.bmc.2015.09.050 ↗
14. Miao, Y., Benwell, K. & Quinn, T. P. 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J. Nucl. Med. 48, 73–80 (2007).
15. Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy research. Cell 140, 313–326 (2010).10.1016/j.cell.2010.01.028 ↗
16. Nelson, D. A. et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 18, 2095–2107 (2004).10.1101/gad.1204904 ↗
17. Kandasamy, K. et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 63, 1712–1721 (2003).
18. Jacobson, M. D. et al. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361, 365–369 (1993).10.1038/361365a0 ↗
19. He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100–1111 (2009).10.1016/j.cell.2009.05.021 ↗
20. Liu, Y. et al. Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc. Natl Acad. Sci. USA 110, 20364–20371 (2013).10.1073/pnas.1319661110 ↗
21. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).10.1016/j.cell.2012.03.042 ↗
22. Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836–16841 (2014).10.1073/pnas.1415518111 ↗
23. Ruhrberg, C. & De Palma, M. A double agent in cancer: deciphering macrophage roles in human tumors. Nat. Med. 16, 861–862 (2010).10.1038/nm0810-861 ↗
24. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. & Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437–3446 (2005).10.1158/0008-5472.CAN-04-4262 ↗
25. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).10.1038/nri2448 ↗
26. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).10.1016/j.cell.2013.12.010 ↗
27. Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).10.1038/ncb3064 ↗
28. Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).10.1016/j.molcel.2015.06.011 ↗
29. Gabizon, A. et al. Cancer nanomedicines: closing the translational gap. Lancet 384, 2175–2176 (2014).10.1016/S0140-6736(14)61457-4 ↗
30. Ma, K., Zhang, D., Cong, Y. & Wiesner, U. Elucidating the mechanism of silica nanoparticle PEGylation processes using fluorescence correlation spectroscopies. Chem. Mater. 28, 1537–1545 (2016).10.1021/acs.chemmater.6b00030 ↗
31. Roveri, A., Maiorino, M. & Ursini, F. Enzymatic and immunological measurements of soluble and membrane-bound phospholipid-hydroperoxide glutathione peroxidase. Methods Enzymol. 233, 202–212 (1994).10.1016/S0076-6879(94)33023-9 ↗
32. Zeger, S. L., Liang, K. Y. & Albert, P. S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44, 1049–1060 (1988).10.2307/2531734 ↗